Small caps round-up: Expansys, Scancell, Inspired Energy...
Expansys, Scancell, Inspired Energy, Angel Biotechnology
Expansys, the eCommerce company, has struck lucky in Istanbul. Its subsidiary PJ Media has won a contract to supply the official online store for Vodafone Turkey. By 11:06 eXpansys had gained 8.6%.
Scancell Holdings, the developer of therapeutic cancer vaccines, has announced it has recruited enough patients to start a Phase I clinical trial of SCIB1, its DNA vaccine being developed for the treatment of melanoma. By 11:12 the stock had risen 4.4%.
Inspired Energy has completed its acquisition of Direct Energy Purchasing. The initial consideration is for £2m (in cash and shares), plus two deferred payments of up to £1m each based primarily upon the financial performance of DEP. By 11:29 the stock had risen 6.2%.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Angel Biotechnology, the biopharmaceutical contract manufacturer, has agreed a contract with US outfit TransGenRx for the development and scale up of a recombinant interferon product. The shares were up 1.27% by 11:12.
BS
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Emotional investing: what is it and how you can avoid it
Are you an emotional investor? Your feelings could be damaging your long-term investments, but here's how to stay rational when the markets are turbulent.
-
'Angela Rayner taking charge of government policy is a frightening prospect for UK economy'
Opinion Deputy prime minister Angela Rayner is making moves to change the direction of our government. That should terrify us all, says Matthew Lynn